Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Circulating metabolites in progression to islet autoimmunity and type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Fenofibrate increases very-long-chain sphingolipids and improves blood glucose homeostasis in NOD mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Role of fasting duration and weekday in incretin and glucose regulation

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIMS/HYPOTHESIS: Glucagon-like peptide 1 (GLP-1) reduces appetite and energy intake in humans, whereas the other incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), seems to have no effect on eating behaviour. Interestingly, studies in rodents have shown that concomitant activation of GIP and GLP-1 receptors may potentiate the satiety-promoting effect of GLP-1, and a novel dual GLP-1/GIP receptor agonist was recently shown to trigger greater weight losses compared with a GLP-1 receptor agonist in individuals with type 2 diabetes. The aim of this study was to delineate the effects of combined GIP and GLP-1 receptor activation on energy intake, appetite and resting energy expenditure in humans.

METHODS: We examined 17 overweight/obese men in a crossover design with 5 study days. On day 1, a 50 g OGTT was performed; on the following 4 study days, the men received an isoglycaemic i.v. glucose infusion (IIGI) plus saline (154 mmol/l NaCl; placebo), GIP (4 pmol kg-1 min-1), GLP-1 (1 pmol kg-1 min-1) or GIP+GLP-1 (4 and 1 pmol kg-1 min-1, respectively). All IIGIs were performed in a randomised order blinded for the participant and the investigators. The primary endpoint was energy intake as measured by an ad libitum meal after 240 min. Secondary endpoints included appetite ratings and resting energy expenditure, as well as insulin, C-peptide and glucagon responses.

RESULTS: Energy intake was significantly reduced during IIGI+GLP-1 compared with IIGI+saline infusion (2715 ± 409 vs 4483 ± 568 kJ [mean ± SEM, n = 17], p = 0.014), whereas there were no significant differences in energy intake during IIGI+GIP (4062 ± 520 kJ) or IIGI+GIP+GLP-1 (3875 ± 451 kJ) infusion compared with IIGI+saline (p = 0.590 and p = 0.364, respectively). Energy intake was higher during IIGI+GIP+GLP-1 compared with IIGI+GLP-1 infusion (p = 0.039).

CONCLUSIONS/INTERPRETATION: While GLP-1 infusion lowered energy intake in overweight/obese men, simultaneous GIP infusion did not potentiate this GLP-1-mediated effect.

TRIAL REGISTRATION: ClinicalTrials.gov NCT02598791 FUNDING: This study was supported by grants from the Innovation Fund Denmark and the Vissing Foundation.

Original languageEnglish
JournalDiabetologia
Volume62
Issue number4
Pages (from-to)665-675
Number of pages11
ISSN0012-186X
DOIs
Publication statusPublished - 1 Apr 2019

    Research areas

  • Appetite, Dual receptor agonism, Energy expenditure, Energy intake, Glucagon-like peptide 1, Glucose-dependent insulinotropic polypeptide, Obesity, Overweight

ID: 56361861